Arbutus Biopharma Corp (ABUS)vsargenx NV ADR (ARGX)
ABUS
Arbutus Biopharma Corp
$4.25
-2.30%
HEALTHCARE · Cap: $884.97M
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 2377% more annual revenue ($4.74B vs $191.44M). ABUS leads profitability with a 84.0% profit margin vs 31.4%. ABUS trades at a lower P/E of 5.4x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ABUS
Buy63
out of 100
Grade: C+
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABUS.
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 62 in profit
Keeps 84 of every $100 in revenue as profit
Strong operational efficiency at 94.4%
Revenue surging 10055.0% year-over-year
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABUS
The strongest argument for ABUS centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 84.0% and operating margin at 94.4%. Revenue growth of 10055.0% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bear Case : ABUS
The primary concerns for ABUS are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ABUS carries more volatility with a beta of 0.62 — expect wider price swings.
ABUS is growing revenue faster at 10055.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 63/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arbutus Biopharma Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?